Novartis’s Chinook takeout gives a boost to others pursuing this long-researched target, including Vera and Alpine.
Biogen and Denali stand out among small developers targeting Parkinson's.
Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.
A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.
Chinook, Vertex and Dimerix are following Travere in FSGS, but several dropouts point to challenges in this disease.
The group is fast developing its new atrial fibrillation devices. But will it be fast enough?
Immune agents old and new are trying to make a splash in what could turn into a billion-dollar market.
The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.
As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?